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Complications of the diabetic pregnancy include
an increased risk of maternal hypertension and
sudden, unexplained fetal death. Each may be
associated with an increased tendency for throm-
bosis. Abnormalities of both soluble coagulation
components and platelet function are present in
diabetic patients with advanced vascular disease.
These alterations support the concept of a hyper-
coagulable state. Endothelial cells from diabetic
patients release increased quantities of von WlLLE-
BRAND's factor [8, 12]. Both platelet adhesion and
aggregability are increased; metabolism is altered.
The increased adhesiveness may be secondary to
fibrin coating of the platelet [17, 10]. Fibrinogen
is frequently elevated; fibrinolysis is depressed [8].
Antithrombin III, the principle in vivo inhibitor of
thrombin generation, has variously been reported
as increased, decreased, or unchanged in patients
with diabetes [1, 2, 9]. The discrepancy may
be secondary to differences in the degree of
vascular disease. Indeed, increased antithrombin HI
activity may be an early compensatory response to
increased fibrin generation [8]. Some investigators
have reported improvement of these coagulation
parameters after sustained periods of eugiycemia
[18, 7, 13, 5, 6]. Whether some or all of these
abnormalities are present in the diabetic patient
without advanced vascular disease is unclear [3].
Further, it is difficult to distinguish whether these
coagulation abnormalities are the direct result of
hyperglycemia or secondary to an indirect effect
upon the vascular endothelial cell.
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Measurement of fibrin turnover is one way of
documenting hypercoagulability. Fibrin cata-
bolism has not previously been examined in the
diabetic pregnancy. Fibrinopeptide A is the first
peptide cleaved from fibrinogen during thrombin-
mediated fibrin generation [15]. With a three
minute half-life, FPA concentration reflects
current fibrin generation. We have previously
demonstrated that the level of FPA increases
during normal pregnancy with the advancement of
gestational age [19]. The findings of the current
study suggest that fibrin catabolism is further
increased in the pregnant diabetic patient despite
aggressive blood glucose control.
1 Materials and methods
As part of an investigation into coagulation abnor-
malities during pregnancy, FPA was prospectively
and longitudinally determined by radioimmuno-
assay in 20 pregnant, diabetic women between
26 and 38 weeks' gestational age. Women in
WHITE'S classes B—F received insulin two to four
times per day and performed home monitoring.
The insulin adjustments were based on preprandial
measurements; these were unavailable for our
analyses. The overall diabetic control was deter-
mined by total hemoglobin Al (HbA^ and fasting
plasma glucose levels which were available from
the patient records. Total HbAj was measured
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using the CORNING electrophoretic method.
Plasma glucose was determined with a BECKMAN
glucose analyzer. All determinations included were
computed from individual patient means.
Fibrinopeptide A was measured by an investiga-
tional, double antibody radioimmunoassay kit
developed by MALLINCKRODT, Inc., St. Louis,
Missouri. All assays were performed using a single
production lot. This assay is now commercially
available. Early investigation demonstrated that
paired samples from the opposite arms of volun-
teers using vacutainer and syringe yielded similar
measurements. Plasma was prepared by centrifuga-
tion in a tabletop centrifuge at 1800 χ g for 20
minutes at room temperature. The resulting super-
* natant was stored at — 40°C until assayed. Repro-
ducibility was excellent. Intra-assay and interassay
variations for FPA in the laboratory were 2 % and
4% respectively. A single AT III determination at
36 weeks' gestation was available in some patients
(N = 15). Antithrombin III activity was deter-
mined by the method of ODEGAARD [16]. The
mean FPA concentration of the diabetic women at
each gestational age was compared using the
WlLCOXAN Rank Sum Test, to the corresponding
value obtained from 17 nondiabetic women sam-
pled longitudinally during the study interval [19].
Statistical significance was assumed if ρ < 0.05.
Tab. II. Mean fibrinopeptide A in diabetic women during
pregnancy
G.A.
26 weeks
28 weeks
30 weeks
32 weeks
34 weeks
36 weeks
38 weeks
Normal
FPA
ng/ml ± 1 SD
3.3 ± 0.7
3.9 ± 0.3
4.1 ± 2.1
4.7 ± 1.2
4.3 ± 1.3
4.6 ± 1.9
4.5 ± 1.6
Diabetes (N)
FPA
ng/ml ± 1 SD
3.9 ± 1.4 (12)
*7.0±4.2 (9)
*5.8 ± 2.1 (13)
4.9 ± 1.9 (10)
5.7 ± 2.8 (13)
*6.5 ± 2.8 (14)
*9.5 ±5.5 (6)
*p< 0.05
mean hemoglobin Al ± 1 SD was 7.1% ±1.2%
(N = 54 samples, normal range 4.6—7.0%). The
mean fasting plasma glucose concentration ± 1 SD
was 101.9 mg % ± 21.5 mg % (N = 240 samples).
Mean FPA for the diabetic women exceeded con-
trol values at each gestational period. Despite large
standard deviations, significant differences were
found in four of the seven intervals (Tab. II).
While the highest FPA value was noted in a patient
with advanced diabetic vasculopathy, exclusion of
this patient did not alter the overall findings. Anti-
thrombin III activity at 36 weeks was similar to
control (91.3 vs. 82.3, ρ > 0.05).
2 Results
Patient age ranged from 23 to 36 years (mean
= 28 ± 4.2 years) (Tab. I). Fourteen women were
WHITE'S class A-C. Good diabetic control for
the group overall is indicated by near normal
HgAj and fasting plasma glucose values. The
Tab. I. Demographic characteristics
WHITE'S Class (N)
A (2)
Β (9)
C (3)
D,F,R (6)
* Mean Total HbAj
** Mean Fasting Plasma Glucose
Mean Age ± 1 SD
32
28.5 ± 4.5
25.7 ± 2.9
' 27.5 ± 4.2
7.1 ± 1.2
101.9 ± 21.5 mg%
* mean of 18 individual patient means
** mean of 20 individual patient means
3 Discussion
The present data suggest that fibrinogen cata-
bolism, as reflected by the level of FPA, was
elevated above normal pregnancy in women with
diabetes mellitus. Interpretation of these findings
should be cautious in light of the large standard
deviations and the sampling errors. Not all patients
were sampled at each gestational epoch. Because
these women were involved in a study not designed
to evaluate abnormalities of coagulation specif-
ically secondary to diabetes, correlations with con-
trol and WHITE'S class would not be valid. Never-
theless, the findings were striking and suggested
the need for a prospective study designed to
account for WHITE'S, classification of diabetes and
the degree of glucose control.
In light of the known coagulation abnormalities
present in nonpregnant diabetic patients, our
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findings are not altogether surprising. However,
the possible causes and the effects of accelerated
fibrinogen catabolism during pregnancy upon the
mother and fetus should be considered. We have
previously supported the concept of a hyper-
coagulable milieu during normal pregnancy by
demonstrating elevated FPA levels [19]. Com-
plications of the diabetic pregnancy include an
increased risk of hypertension in the mother, and
sudden, unexplained fetal loss. Each has been
associated with an increased tendency for throm-
bosis.
It is possible that the hypercoagulability of preg-
nancy is enhanced by the diabetic disease process,
and accounts at least in part for the elevated FPA
concentrations detected. Reduced prostacyclin
production by the umbilical arteries during in vitro
stimulation of infants born to diabetic mothers has
been reported. If such a decrease occurs on the
maternal side, the reduced prostacyclin/throm-
boxane A2 ratio could promote thrombogenesis
and fibrin generation [14]. Poor glucose control
might also contribute since large excursions of
plasma glucose results in excessive- free water
movement to and from the intravascular space
producing blood flow turbulence at arterial branch
points and disruption of the endothelial layer [4].
Another possible explanation of the high FPA
observed in the diabetic pregnancy involves the
pregnancy-related increase in blood flow to various
organs. Elevated plasma beta-thromboglobulin and
platelet factor 4, indicative of platelet consump-
tion, have been reported in patients with such
vascular diseases as coronary artery disease, peri-
pheral vascular disease, and diabetic angiopathy
[10]. Normal blood flow turbulence is increased at
the arteriolar branch points and can lead to endo-
thelial cell damage, platelet activation, and sub-
sequent fibrin generation [8], This turbulence is
further increased at sites of atherosclerotic disease.
Therefore, increased blood flow during pregnancy
to organs with asymptomatic vascular disease, such
as the kidney, could contribute to an elevated
FPA. An elevated FPA in a pregnant diabetic
woman, despite euglycemic control, might identify
her as likely to develop clinically evident diabetic
angiopathy in the near future. Such information
would be of value. If eugjycemia decreases the rate
at which angiopathy progresses, these patients
would benefit from longterm, intensive glucose
control.
In summary, a preliminary investigation of FPA in
pregnant diabetic women suggests that fibrinogen
catabolism is enhanced. Further, this enhancement
occurred despite blood glucose levels which
approximated normal range.
Summary
Fibrin catabolism was measured during the pregnancy of
insulin-dependent diabetic women in both a longitudinal
and cross sectional fashion. Samples of maternal peri-
pheral venous blood were obtained in 20 pregnant diabe-
tic women between 26 and 38 weeks* gestational age.
Fibrinopeptide A, the first peptide cleaved from fibrino-
gen during thrombin-mediated catabolism, was measured
by radioimmunoassay. Intra-assay and interassay variation
for fibrinopeptide A in this laboratory were 2 % and 4 %
respectively. Antithrombin III activity was determined by
the method of ODEGAARD. The patients ranged from 23
to 36 years. Overall blood glucose control was good as
reflected in near-normal HbA1 fasting plasma glucose
values. The mean HbAj ± 1 standard deviation was
7.1% ± 1.2%. The mean fasting plasma glucose concen-
tration was 101.9 mg% ± 21.5 mg%. Mean FPA for the
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diabetic women exceeded control values at each gesta-
tional period. Significant differences were found in four
of the seven intervals. While the highest FPA was noted in
a patient with advanced diabetic vasculopathy, exclusion
of this patient did not alter the overall findings. The
findings were striking and suggest the need for a prospec-
tive study designed to account for WHITE'S classification
of diabetes and the degree of glucose control. Because
complications of the diabetic pregnancy include an
increased risk of hypertension in the mother and sudden,
unexplained fetal loss, two complications associated with
abnormal clotting, the increase in fibrin catabolism in
patients in tight metabolic control would suggest that
events other than glucose regulation impact upon fibrin
catabolism and possibly pregnancy outcome in the
diabetic mother.
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Zusammenfassung
Fibrinbildung in diabetischen Schwangerschaften
Wir untersuchten den Fibrinstoffwechsel bei insulinpflich-
tigen diabetischen Schwangeren sowohl in Longitudinal-
als auch in Querschnittsstudien. Dazu wurde bei 20
Diabetikerinnen zwischen der 26. und 38. Schwanger-
schaftswoche peripheres Venenblut abgenommen. Das
Fibrinopeptid A (FPA), welches als erstes Peptid während
des thrombinvermittelten Prozesses vom Fibrinogen abge-
spalten wird, wurde radioimmunologisch bestimmt. In
unserem Labor lag die Streuung für einen bzw. unter-
schiedliche Ansätze bei 2 % bzw. 4 %. Die Antithrombin-
IH-Aktivität wurde nach der Methode von ODEGAARD
bestimmt. Das Alter der Patientinnen lag zwischen 23 und
36 Jahren. Wie das HbAx und die Nüchternblutzucker-
Spiegel zeigen, waren die Diabetikerinnen gut eingestellt:
das HbAi betrug im Mittel 7,1 % ± 1,2%, der Nüchtern-
blutzucker 101,9 mg% ± 21,5 mg%. Der FPA-Spiegel bei
diabetischen Schwangeren lag zu jedem Zeitpunkt der
• Schwangerschaft oberhalb der Vergleichskontrolle. Dabei
Schlüsselwörter: Diabetes, Fibrinopeptid A.
• r
waren in 4 von 7 Zeitintervallen die Unterschiede stati-
stisch signifikant. Die höchsten FPA-Spiegel wurden
bei einer Patientin mit fortgeschrittener diabetischer
Vaskulopäthie gefunden. Auch wenn man diese Werte
herausnahm, änderte sich das Gesamtergebnis nicht. Die
Ergebnisse waren beeindruckend und legen nahe, eine
prospektive Studie unter Berücksichtigung der Diabetes-
Klassifikation nach WHITE und der Abstufung der
Blutzuckerkontrollen durchzuführen. Bei diabetischen
Schwangerschaften besteht ein erhöhtes Risiko für einen
Hypertonus der Mutter sowie für eine Fehlgeburt, wobei
beide Komplikationen mit einer abnormen Gerinnung
assoziiert sind. Ein erhöhter Fibrinkatabolismus bei
Patientinnen mit strenger Stoffwechselführung deutet
darauf hin, daß neben der Glukoseregulation andere
Mechanismen auf den Fibrinstoffwechsel und den
Schwangerschaftsverlauf bei diabetischen Patientinnen
einwirken.
Resume
Production de fibrine au cours de la grossesse chez la
diabetique
On a mesure le catabolisme de la fibrine au cours de la
grossesse de femmes diabetiques insulino-dependantes, ä
la fois de fagon longitudinale et ä la fois en sections
croisees. Chez 20 diabetiques enceintes entre 26 et 38
semaines d'äge gestationnel, on a obtenu des preleve-
ments de sang veineux peripherique maternel. Le fibrino-
peptide A, premier peptide coupe du fibrinogene au cours
du catabolisme cediate par la thxombine, a ete dose par
methode radio-immunologique. Les variations de ce labo-
ratoire pour les dosages entre eux ou pour un meme dosage
sont de 4 % et de 2 % respectivement. On a mesure Facti-
vite d'antithrombine HI par la methode d'ODEGAAD.
Les patientes etaient ägees de 23 ä 36 ans. Le contröle
global de la glycemie etait bon avec des valeurs d'HbAj
proches de la normale ainsi que des valeurs de la glycemie
ä jeün. Les valeurs moyennes d'HbAj^ ± l deviation
Standard etaient de 7,1% ±1,2%. La moyenne des
glycemies ä jeün etait de 101,9 mg % ± 21,5 mg %. La
Mots-cles: Diabete, fibrinopeptide A.
moyenne des FPA chez les diabetiques depassait les
valeurs temoins pour chaque periode gestationnelle.
On a trouve des differences significatives pour 4 des 7
intervalles. Bien que la plus haute valeur de FPA ait ete
trouvee chez une patiente presentant une vasculopathie
diabetique avancee, Fexclusion de cette patiente n'a pas
altere les donnees globales. Les donnees sont eclatantes et
suggerent la necessite d'une etude prospective destinee a
verifier la classification des diabetes de WHITE et le degre
du contröle glucidique. En raison des complications de la
grossesse de la diabetique comprenant un risque accru
d'hypertension materneUe et des morts foetales brutales et
inexpliquees, ces deux complications s'accompagnent
d'une coagulation anormale, l'augmentation du cata-
bolisme de la fibrine, chez des patientes avec un etroit
contröle metabolique suggererait que des facteurs autres
que la regulation glucidique agissent sur le catabolisme
de la fibrine et peut-etre sur revolution de la grossesse des
meres diabetiques.
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